An international study led by Memorial Sloan-Kettering found that pazopanib (Votrient^®) controls cancer as effectively as sunitinib (Sutent^®) while improving patients’ quality of life.

A Memorial Sloan-Kettering study suggests that lymphedema of the arm, a swelling that can occur following breast cancer treatment, may be reduced by acupuncture.

A study has found that the majority of kidney cancer patients with small tumors have their entire kidney removed, which can increase the risk of developing chronic kidney disease and cardiovascular complications.

Early research led by investigators at Memorial Sloan-Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Our doctors have shown that tumors compressing the spinal cord can be controlled using less-invasive surgery combined with a precise, intense form of radiation therapy.

Memorial Sloan-Kettering experts add to their knowledge of vemurafenib, a drug recently approved by the FDA to treat some patients with metastatic melanoma.